Vivek Subbiah: Interesting commentary on Weight gain and ALK inhibitors by Cathleen June Park, et al.

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a recent article by Cathleen June Park, et al, on LinkedIn:

“A recent paper published in the Journal of Clinical Oncology raised our awareness of excessive weight gain with ALK inhibitor- alectinib treatment.

Interesting commentary on Weight gain and ALK inhibitors.

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung Cancer?”

Authors: Cathleen June Park, Alexandria T.M. Lee, Sai-Hong Ignatius Ou.

More posts featuring Vivek Subbiah.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.